Open AccessContinuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?
Author(s) -
Dennis M. Black,
Douglas C. Bauer,
Ann V. Schwartz,
Steven R. Cummings,
Clifford J. Rosen
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmp1202623
Subject(s) - medicine , bisphosphonate , osteoporosis , osteonecrosis of the jaw , bone density conservation agents , intensive care medicine , surgery , pediatrics , dentistry , bone density
There is controversy over the ideal duration of bisphosphonate therapy for osteoporosis, given reports of atypical subtrochanteric fractures and osteonecrosis of the jaw. But some subgroups of patients may benefit from continuing therapy beyond 3 to 5 years.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom